|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
This CLN-Ohi-MB biochip could quantify single-point mutations in KRAS mRNA (G12C, G12D, G12V) in pancreatic cancer cell-derived EVs and single-point mutations in EGFR mRNA (L858R and T790M) in lung cancer cell-derived EVs with high specificity, not achievable by conventional molecular probes.
|
30145409 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Changes of T790M in serum/plasma in <i>EGFR</i>-mutant lung cancer patients with T790M-AR might be a useful marker of symptomatic and radiographic outcome to osimertinib.
|
29930751 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.
|
29462256 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our drug inhibition studies indicate that these activating insertion mutations respond more favorably to osimertinib, a recently Food and Drug Administration-approved EGFR inhibitor for T790M-positive patients with lung cancer.
|
30104348 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review.
|
29907952 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.
|
30073261 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Brief Report on the Detection of the EGFR T790M Mutation in Exhaled Breath Condensate from Lung Cancer Patients.
|
29751135 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Pitfalls in diagnosis with the use of circulating tumor-derived epidermal growth factor receptor mutations in lung cancer harboring pretreatment T790M.
|
29063709 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient.
|
30151614 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Different resistance mechanisms, especially, T790M secondary acquired point mutation and in some cases amplification of cMET, have been a major setback for the lung cancer therapies.
|
28362115 |
2017 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Specifically, these agents can overcome the effects of the T790M mutation, which mediates resistance to first- and second-generation EGFR TKI, and recent clinical trials have documented their efficacy in patients with <i>EGFR</i>-mutant lung cancer.
|
28416483 |
2017 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
As this clinical entity is underrepresented in clinical trials, the practicability of plasma EGFR testing and the optimal dose-response relationship of osimertinib in T790M-positive lung cancer complicated with LM deserves further exploration.
|
28296233 |
2017 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Amplification-refractory mutation system PCR has been used for the analysis of ctDNA to detect resistance-causing mutations in the epidermal growth factor receptor gene (eg, EGFR T790M) in lung cancer patients.
|
28732213 |
2017 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Staurosporine scaffold-based rational discovery of the wild-type sparing reversible inhibitors of EGFR T790M gatekeeper mutant in lung cancer with analog-sensitive kinase technology.
|
27891677 |
2017 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The present study established lung cancer cell lines that were resistant to gefitinib or erlotinib, and these cell lines were verified to contain the <i>EGFR</i> T790M mutation.
|
28781659 |
2017 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Lung cancer harboring epidermal growth factor receptor (EGFR) mutations and treated with EGFR tyrosine kinase inhibitors (TKIs) all eventually develop acquired resistance to the treatment, with half of the patients developing EGFR T790M resistance mutations.
|
28620690 |
2017 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Nowadays, 3rd generation EGFR TKI is widely used for T790M positive 1st and 2nd EGFR-TKI resistant lung cancer patients.
|
28684311 |
2017 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, we analyzed 55 cfDNA preparations from patients with lung cancer to compare reliability and sensitivity of the three methods under routine conditions and achieved 96.0% concordance of p.T790M results.
|
28723342 |
2017 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, we introduced the EGFR T790M mutation into the PC9 human lung cancer cell line-which has a deletion in exon 19 of the EGFR gene-by clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas)9-mediated genome editing.
|
28422737 |
2017 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer.
|
28778263 |
2017 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
|
27959700 |
2017 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403.
|
27506489 |
2017 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer.
|
28082405 |
2017 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Monitoring T790M with plasma DNA using MBP-QP reflects the clinical course of lung cancer patients treated with EGFR-TKI.
|
26577492 |
2016 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
This review summarizes information about and current treatment strategies for patients with EGFR-mutant lung cancer whose disease progresses on their initial EGFR inhibitor, including those with T790M and other types of acquired resistance.
|
27196961 |
2016 |